PHAR חוב כולל להון Pharming Corp
The debt-to-equity dynamics of Pharming Group N.V. (PHAR) demonstrate financial stability, where the value of 0.40 describes the current leverage level. A monopoly on a unique drug for rare pathologies allows the company to exercise pricing power. Despite geopolitical risks in supply chains, stable demand for the core medication ensures a consistent cash generator.
פילוחים אנליטיים ודוחות נתונים של חברת Pharming Corp (PHAR)
Pharming Group N.V. specializes in biopharmaceuticals, delegating the production of protein-based drugs to external CMO partners. This metric compares total liabilities to equity to assess the business's leverage. This allows the investor to determine the company's financial stability given its high operational dependence on outsourcing. A decrease in this ratio confirms the effectiveness of risk management. By analyzing changes in the total debt-to-equity level, one can evaluate the alignment of management's strategy with reality.